Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea

PURPOSE: Adoptive cell immunotherapy involves an ex vivo expansion of autologous cytokine-induced killer (CIK) cells before their reinfusion into the host. We evaluated the efficacy and safety of CIK cell immunotherapy with radiotherapy-temozolomide (TMZ) for the treatment of newly diagnosed gliobla...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Kong, Doo-Sik, Nam, Do-Hyun, Kang, Shin-Hyuk, Lee, Jae Won, Chang, Jong-Hee, Kim, Jeong-Hoon, Lim, Young-Jin, Koh, Young-Cho, Chung, Yong-Gu, Kim, Jae-Min, Kim, Choong-Hyun
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Clinical Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5351686/
https://ncbi.nlm.nih.gov/pubmed/27690294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12273
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items